Gryphon has a set of protein engineering technologies for creating even very large synthetic proteins, useful for modifying existing protein therapeutics to improve them as drugs, creating multivalent artificial therapeutics and vaccines, and doing rapid structure-function analysis of newly uncovered proteins.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.